Autopsy report · NCT00752206
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Cause of deathFutility, also safety
“The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 8 years 9 months before it stopped.
- 38 participants enrolled.
- Results were posted on the registry 2 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Sponsor type
- University, hospital or other
- Conditions
- Osteosarcoma
- Interventions
- Saracatinib; Placebo
- Participants
- 38
- Sites
- 18
- Countries
- United States
Trials that died the same way
- Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
“Data Safety Monitoring Board (DSMB) recommended stopping study due to futility” - ATG Plus Low-dose PT-Cy for GVHD Prevention
“DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
“Following a recommendation from the Data Safety Monitoring Board (DSMB).” - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
“Interim analysis-DSMB stated good safety profile but lack of efficacy” - Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
“DSMB recommended termination because TI was safe but not durable.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.